EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
Partnerships
BenevolentAI and AstraZeneca collaborate on novel target for heart failure
AI Drug Discovery
May 15, 2024
This week:
Product updates
Stability AI launches Stable Diffusion 3 Medium, a text-to-image model
Foundation Models
Yesterday
Product updates
Microsoft discontinues GPT Builder in Copilot
Generative AI Applications
Yesterday
Funding
BlinqIO raises USD 5 million in funding to expand operations
Generative AI Applications
Yesterday
Product updates
Databricks launches innovations to Mosaic AI for production-quality applications
Generative AI Infrastructure
Yesterday
M&A
Rebellions and Sapeon Korea merge to challenge global AI chip leader
Generative AI Infrastructure
Yesterday
M&A
Pluxee to acquire Cobee; expands employee benefits offering
Remote Work Infrastructure
Yesterday
Product updates
Space and Time launches 'Proof of SQL' solution on GitHub
Enterprise Blockchain Solutions
Yesterday
Partnerships
Lido partners with Mellow Finance to launch liquid restaking vaults
Decentralized Finance (DeFi)
Yesterday
Funding
Rivia raises EUR 3 million in seed funding
Clinical Trial Technology
Yesterday
Product updates
Partnerships
Databricks and Shutterstock collaborate to launch enterprise-optimized ImageAI model
Generative AI Infrastructure
Yesterday
AI Drug Discovery

AI Drug Discovery

May 15, 2024

BenevolentAI and AstraZeneca collaborate on novel target for heart failure

Partnerships

  • BenevolentAI has announced that a new heart failure target has been added to its discovery portfolio by AstraZeneca through their ongoing collaboration. This novel heart failure target was identified using BenevolentAI's AI-driven drug discovery platform and subsequently validated experimentally by AstraZeneca.

  • The partnership was initiated in 2019 for the exchange of technology and biomedical knowledge from BenevolentAI and scientific expertise from AstraZeneca for effective target identification. The studies initially focused on idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD) and have expanded to include heart failure and Systemic Lupus Erythematosus (SLE).

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.